AbbVie Closes $10.9 Billion Acquisition of Apogee Therapeutics

MT Newswires Live

Yesterday

AbbVie (ABBV) said Thursday that it has completed its acquisition of Apogee Therapeutics (APGE), valuing the clinical-stage biotechnology company at about $10.9 billion, or $135.11 per share.

The acquisition is expected to negatively impact adjusted diluted earnings per share by $0.14 in 2026 and by approximately $0.46 in 2027, with accretion beginning in 2032, AbbVie said.

Apogee Therapeutics' stock ceased trading on the Nasdaq stock exchange prior to the market open on Sept. 3, according to a statement.

AbbVie said it continues to expect Q3 adjusted diluted EPS in the range of $3.84 to $3.88, and full-year adjusted diluted EPS between $13.87 to $14.07.

Analysts polled by FactSet expect $3.86 and $14.03, respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/news/2664720938"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2664720938\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2664720938?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-03 21:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2664720938","market":"fut","top_or_hot":-1,"title":"AbbVie Closes $10.9 Billion Acquisition of Apogee Therapeutics","media":"MT Newswires Live","content":"<html><body><p> AbbVie (ABBV) said Thursday that it has completed its acquisition of <a href=\"https://laohu8.com/S/APGE\">Apogee Therapeutics</a> (APGE), valuing the clinical-stage biotechnology company at about $10.9 billion, or $135.11 per share.</p><p>The acquisition is expected to negatively impact adjusted diluted earnings per share by $0.14 in 2026 and by approximately $0.46 in 2027, with accretion beginning in 2032, AbbVie said.</p><p>Apogee <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' stock ceased trading on the Nasdaq stock exchange prior to the market open on Sept. 3, according to a statement.</p><p>AbbVie said it continues to expect Q3 adjusted diluted EPS in the range of $3.84 to $3.88, and full-year adjusted diluted EPS between $13.87 to $14.07.</p><p>Analysts polled by FactSet expect $3.86 and $14.03, respectively.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AbbVie Closes $10.9 Billion Acquisition of Apogee Therapeutics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbbVie Closes $10.9 Billion Acquisition of Apogee Therapeutics\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-03 21:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> AbbVie (ABBV) said Thursday that it has completed its acquisition of <a href=\"https://laohu8.com/S/APGE\">Apogee Therapeutics</a> (APGE), valuing the clinical-stage biotechnology company at about $10.9 billion, or $135.11 per share.</p><p>The acquisition is expected to negatively impact adjusted diluted earnings per share by $0.14 in 2026 and by approximately $0.46 in 2027, with accretion beginning in 2032, AbbVie said.</p><p>Apogee <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' stock ceased trading on the Nasdaq stock exchange prior to the market open on Sept. 3, according to a statement.</p><p>AbbVie said it continues to expect Q3 adjusted diluted EPS in the range of $3.84 to $3.88, and full-year adjusted diluted EPS between $13.87 to $14.07.</p><p>Analysts polled by FactSet expect $3.86 and $14.03, respectively.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PPH","symbol_name":"VanEck Pharmaceutical ETF","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2664720938","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2664720938","pubTimestamp":1788441193,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"AbbVie  said Thursday that it has completed its acquisition of Apogee Therapeutics , valuing the clinical-stage biotechnology company at about $10.9 billion, or $135.11 per share.The acquisition is expected to negatively impact adjusted diluted earnings per share by $0.14 in 2026 and by approximately $0.46 in 2027, with accretion beginning in 2032, AbbVie said.Apogee Therapeutics' stock ceased trading on the Nasdaq stock exchange prior to the market open on Sept. 3, according to a statement.AbbVie said it continues to expect Q3 adjusted diluted EPS in the range of $3.84 to $3.88, and full-year adjusted diluted EPS between $13.87 to $14.07.Analysts polled by FactSet expect $3.86 and $14.03, respectively.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PPH":"VanEck Pharmaceutical ETF","AGNG":"Global X Aging Population ETF","MEDX":"HORIZON KINETICS MEDICAL ETF","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","IXJ":"全球医疗业ETF-iShares","PJP":"INVESCO PHARMACEUTICALS ETF","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU0949170772.SGD":"Blackrock Global Equity Income A6 SGD-H","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","LU2125909247.SGD":"Natixis Thematics Meta H-R/A SGD","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","TRUH":"VanEck Healthcare TruSector ETF","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","IYH":"iShares U.S. Healthcare ETF","IE00BVYPNV92.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) ACC","FTXH":"First Trust Nasdaq Pharmaceuticals ETF","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","LU1923622614.USD":"Natixis Thematics Meta R/A USD","GLAM":"Corgi Beauty, Skincare & Aesthetics ETF","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","LU0289961442.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (SGD) ACC","JDOC":"JPMORGAN HEALTHCARE LEADERS ETF","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","XLV":"健康照护类股ETF-SPDR","FHLC":"Fidelity MSCI Health Care Index","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU0069063385.USD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (USD) ACC","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","APGE":"Apogee Therapeutics","ABBV":"艾伯维公司","VHT":"Vanguard Health Care ETF","RXL":"ProShares Ultra Health Care","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","LU0057025933.USD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (USD) ACC","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU0289739343.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (SGD) ACC","SBIO":"ALPS Medical Breakthroughs ETF","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","LU2129689514.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) INC"},"translate_title":"艾伯维完成 109 亿美元收购 Apogee Therapeutics","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IXJ":0.6,"FTXH":0.6,"APGE":1.5,"MEDX":0.6,"TRUH":0.6,"AGNG":0.6,"ABBV":1.5,"VHT":0.6,"PPH":0.6,"PJP":0.6,"GLAM":0.6,"RXL":0.6,"IYH":0.6,"JDOC":0.6,"XLV":0.6,"SBIO":0.6,"FHLC":0.6},"content_text":"AbbVie (ABBV) said Thursday that it has completed its acquisition of Apogee Therapeutics (APGE), valuing the clinical-stage biotechnology company at about $10.9 billion, or $135.11 per share.The acquisition is expected to negatively impact adjusted diluted earnings per share by $0.14 in 2026 and by approximately $0.46 in 2027, with accretion beginning in 2032, AbbVie said.Apogee Therapeutics' stock ceased trading on the Nasdaq stock exchange prior to the market open on Sept. 3, according to a statement.AbbVie said it continues to expect Q3 adjusted diluted EPS in the range of $3.84 to $3.88, and full-year adjusted diluted EPS between $13.87 to $14.07.Analysts polled by FactSet expect $3.86 and $14.03, respectively.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}